BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

ORIONPHARM

All Eps Dividend Board Agm Q1 Q2 Q3

ORIONPHARM 15-Dec-2020

Trading of the shares of the Company will remain suspended on record date i.e., 17.12.2020 for EGM.

ORIONPHARM 13-Dec-2020

Trading of the shares of the Company will be allowed only in the Spot Market and Block transactions will also be settled as per Spot settlement cycle from 14.12.2020 to 15.12.2020. Trading of the shares of the Company will remain suspended on record date i.e., 17.12.2020 for EGM.

ORIONPHARM 29-Nov-2020

Trading of the shares of the Company will resume on 30.11.2020 after record date.

ORIONPHARM 29-Nov-2020

The Company has further informed that the Board has advised to convene an EGM for the proposal for approval of the shareholders regarding Related Party Transactions of OPL for the financial year ended on June 30, 2020. Date of the EGM: December 23, 2020 at 4:45 PM on a Digital Platform. Record Date: 17.12.2020.

ORIONPHARM 26-Nov-2020

Trading of the shares of the Company will remain suspended on record date i.e., 29.11.2020.

ORIONPHARM 24-Nov-2020

Trading of the shares of the Company will be allowed only in the Spot Market and Block transactions will also be settled as per Spot settlement cycle with cum benefit from 25.11.2020 to 26.11.2020. Trading of the shares of the Company will remain suspended on record date i.e., 29.11.2020.

ORIONPHARM 15-Nov-2020

(Q1 Un-audited): Consolidated EPS was Tk. 0.82 for July-September 2020 as against Tk. 1.17 for July-September 2019; Consolidated NOCFPS was Tk. 1.46 for July-September 2020 as against Tk. 1.96 for July-September 2019. Consolidated NAV per share (including revaluation surplus) was Tk. 77.81 as on September 30, 2020 and Tk. 76.77 as on June 30, 2020. Consolidated NAV per share (excluding revaluation surplus) was Tk. 69.76 as on September 30, 2020 and Tk. 68.69 as on June 30, 2020.

ORIONPHARM 09-Nov-2020

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 14, 2020 at 5:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2020.

ORIONPHARM 09-Nov-2020

There will be no price limit on the trading of the shares of the Company today (November 9, 2020) for following its corporate declaration. However, as per the BSEC Order No. BSEC/CMRRCD/2001-07/04 dated March 19, 2020, the floor price shall be applicable accordingly.

ORIONPHARM 09-Nov-2020

(Cont. of ORIONPHARM): The Company has reported Consolidated EPS of Tk. 2.84, Consolidated NAV per share (Including Revaluation Surplus) of Tk. 76.77, Consolidated NAV per share (Excluding Revaluation Surplus) of Tk. 68.69 and Consolidated NOCFPS of Tk. 8.04 for the year ended on June 30, 2020 as against Tk. 3.77, Tk. 75.19, Tk. 66.98 and Tk. 6.19 respectively for the same period of the previous year. (end)

Previous Next page